Clinical and dosimetric comparison of acute bowel toxicities in carcinoma rectum patients receiving neoadjuvant chemoradiotherapy by using standard 3DCRT VS IMRT

https://doi.org/10.53730/ijhs.v6nS1.6026

Authors

  • Poojashree K S MBBS DMRT DNB, Department of Radiation Oncology, Basavatarakam Indo- American Cancer Hospital and Research Institute, Hyderabad
  • Tasneem Rushdi Consultant, Department of Radiation Oncology, Basavatarakam Indo- American Cancer Hospital and Research Institute, Hyderabad
  • A Krishnan Raju Senior Consultant and Head, Department of Radiation Oncology, Basavatarakam Indo- American Cancer Hospital and Research Institute, Hyderabad
  • Devender Reddy Boja Medical Physicist, Department of Radiation Oncology, Basavatarakam Indo- American Cancer Hospital and Research Institute, Hyderabad

Keywords:

Colorectal cancer, TPS planning system, neoadjuvant, chemoradiation

Abstract

Introduction: Colorectal cancer (CRC) is a common cancer worldwide. It is the third most commonly diagnosed cancer in males and the second in females, with more than 1.4 million new cancer cases every year. Around 40,000 people will be effected by rectal cancer for every year, with a 65% survival rate from past 5-year were estimated. The age standardized rate (ASR) for CRC in India is low at 7.2 per 100,000 population in males and 5.1 per 100,000 populations in women. However overall incidence and survival rates were increased due to the screening and early detection. Materials and Methods: The proposed study is a prospective, hospital based, comparative cohort study including the cases admitted to Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, Telangana with clinical features and investigations suggestive of carcinoma rectum and fulfilling the inclusion criteria will be taken up for study. Patients considered as per inclusion criteria admitted in Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, Telangana were selected and the dosimetric data was collected from the TPS planning system and clinically relevant data was collected from the patient’s record from hospital digital interface system.

Downloads

Download data is not yet available.

References

Prachi S. Patil, Avanish Saklani, Pravir Gambhire, Shaesta Mehta, Reena Engineer, Ashwin De’Souza, Colorectal Cancer in India: An Audit from a Tertiary Center in a Low Prevalence Area, Indian J Surg Oncol. 2017 Dec; 8(4): 484–490. DOI: https://doi.org/10.1007/s13193-017-0655-0

Marco Lupattelli, Fabio Matrone, Maria Antonietta, Gabriella Macchia, Elisa Palazzari et.al, Preoperative intensity-modulated radiotherapy with a simultaneous integrated boost combined with Capecitabine in locally advanced rectal cancer: short-term results of a multicentric study, Radiation Oncology;2017(12),139. DOI: https://doi.org/10.1186/s13014-017-0870-4

Lara Hathout, Terence M. Williams, the Impact of Novel Radiation Treatment Techniques on Toxicity and Clinical Outcomes in Rectal Cancer, Curr Colorectal Cancer Rep. 2017 Feb; 13(1): 61–72. DOI: https://doi.org/10.1007/s11888-017-0351-z

Salma K. Jabbour, Shyamal Patel, Joseph M. Herman, Aaron Wild, Suneel N. Nagda, Taghrid Altoos, et al, Intensity-Modulated Radiation Therapy for Rectal Carcinoma Can Reduce Treatment Breaks and Emergency Department Visits,(2012). DOI: https://doi.org/10.1155/2012/891067

Jun Zhao, Weigang Hu, Gang Cai, Jiazhou Wang, Jiang Xie,Jiayuan Peng et al, Dosimetric comparisons of VMAT, IMRT and 3DCRT for locally advanced rectal cancer with simultaneous integrated boost, Oncotarget. 2016; 7:6345-6351. DOI: https://doi.org/10.18632/oncotarget.6401

Mojca Tuta, Nina Boc, Erik Brecelj, Monika Peternel, Vaneja Velenik, Total neoadjuvant therapy vs standard therapy of locally advanced rectal cancer with high-risk factors for failure, World J Gastro intest Oncol, Feb 15, 2021;13(2): 119-130.

Angelica Balingit, Colorectal cancer: What you need to know, Medical news, May 9, 2021.

Monika Ruszkowska, Tomasz Sawicki, A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis, Cancers,2012;13(1).

Marina De Rosa, Ugo Pace, Daniela Rega, Valeria Costabile, Francesca, Duraturo, Genetics, diagnosis and management of colorectal cancer (Review), 2018; 1087-1096. DOI: https://doi.org/10.3892/or.2015.4108

Angelica Balingit, Colorectal cancer: What you need to know, Medical news, May 9, 2021.

Amy Body, Hans Prenen, Sarah Latham, Marissa Lam, Samuel Tipping-Smith, Ajay Raghunath, the role of neoadjuvant chemotherapy in locally advanced colon cancer, Cancer Management and Research, 2021, 13. DOI: https://doi.org/10.2147/CMAR.S262870

Amy Body, Sarah Latham, Jun Beng Kong , Ajay Raghunath , Eva Segelov, Stage III colon cancer: is neoadjuvant chemotherapy ready for prime time?—A narrative review of neoadjuvant chemotherapy for colon cancer, digestive medicine research; 2021. DOI: https://doi.org/10.21037/dmr-20-159

Angelica Balingit, Colorectal cancer: What you need to know, Medical news, May 9, 2021.

Mojca Tuta, Nina Boc, Erik Brecelj, Monika Peternel, Vaneja Velenik, Total therapy vs standard therapy of locally advanced rectal cancer with high-risk factors for failure, World J Gastro intest Oncol, Feb 15, 2021;13(2): 119-130. DOI: https://doi.org/10.4251/wjgo.v13.i2.119

May Cho, Ryan Beechinor, Sepideh Gholami & AxelGrothey, Precision Medicine for the Treatment of Colorectal Cancer: the Evolution and Status of Molecular Profiling and Biomarkers, Current Colorectal Cancer Reports, (2021); 17, 55–68. DOI: https://doi.org/10.1007/s11888-021-00466-7

Published

18-04-2022

How to Cite

Poojashree, K. S., Rushdi, T., Raju, A. K., & Boja, D. R. (2022). Clinical and dosimetric comparison of acute bowel toxicities in carcinoma rectum patients receiving neoadjuvant chemoradiotherapy by using standard 3DCRT VS IMRT. International Journal of Health Sciences, 6(S1), 5171–5189. https://doi.org/10.53730/ijhs.v6nS1.6026

Issue

Section

Peer Review Articles